A Phase 2 interventional study of MGL-3196 (resmetirom) and Placebo in Heterozygous Familial Hypercholesterolemia, sponsored by Madrigal Pharmaceuticals, Inc.. Completed at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 22nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2017, is one of 10 in phase 2, and was the 21st registered.
249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.
Browse Hyperlipoproteinemia Type II studies →5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Australia and 17 more countries
Ages 6–17
Novartis Pharmaceuticals · Sites in Netherlands, United States, Austria and 8 more countries
Ages 2–11
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 20 more countries
Ages 6–11
Verve Therapeutics, Inc. · Sites in Netherlands, United States, Australia and 3 more countries
Ages 18–70
Novartis Pharmaceuticals · Sites in Netherlands, United States, Argentina and 23 more countries
Ages 2–100
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 17 · Phase 4 1
First in 2000; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 116 is below the median of 134 across 178 interventional studies indexed under Hyperlipoproteinemia Type II.
Median enrollment 153 across the 33 interventional studies, 29 across the 2 observational. Of the 28 that completed or were terminated, 15 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 35 have an industry lead sponsor. The 10 most frequent:
Madrigal Pharmaceuticals, Inc. is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Madrigal Pharmaceuticals, Inc. has 1 study filed under Hyperlipoproteinemia Type II — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in participants with Heterozygous Familial Hypercholesterolemia (HeFH).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Drug
Drug: MGL-3196 (resmetirom)
Matching Placebo
Drug: Placebo
Oral
Oral
Mean Percent Change in LDL-C From Baseline To Week 12
LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Mean Change From Baseline to Week 12 of Free Thyroxine (T4)
T4 was assessed at each study visit.
Time frame: Baseline up to Week 12
Mean Change From Baseline to Week 12 of Free Triiodothyronine (T3)
Free T3 was assessed at each study visit.
Time frame: Baseline up to Week 12
Mean Change From Baseline to Week 12 of Thyrotropin (TSH)
TSH was assessed at each study visit.
Time frame: Baseline up to Week 12
Mean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG)
TBG was assessed at all study visits except the Screening Visit.
Time frame: Baseline up to Week 12
Mean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3)
Reverse T3 was assessed at each study visit.
Time frame: Baseline up to Week 12
Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12
Non-HDL-C were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor
Time frame: Baseline up to Week 12
Mean Percent Change In Triglycerides From Baseline To Week 12
Triglycerides were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Mean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12
Lp(a) was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Mean Percent Change in Apolipoprotein CIII From Baseline to Week 12
Apolipoprotein CIII was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Mean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12
ApoB was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Mean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12
The ApoB/ApoA1 ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Mean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12
The Cholesterol/HDL-C Ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Absolute Change in LDL-C From Baseline to Week 12
LDL-C was determined by ultracentrifugation or direct measure . Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline up to Week 12
Percent Change From Baseline in LDL-C at Week 2 and Week 4 in Patients in the 100 mg and the 60 mg Groups
LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
Time frame: Baseline to Week 2 and Week 4
Percent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category
The effect on percent change in LDL-C from baseline to Week 12 was determined by patient exposure category (higher/lower). Patients taking MGL-3196 were categorized into lower and higher exposure groups. Patients in the higher exposure group must either have had estimated Week 2 AUC ≥5,000 mg∙h/L, or if Week 2 AUC \<5,000 mg∙h/L but Week 4 pre-dose concentration \>1.5 ng/mL (if on 60 mg MGL-3196). All other patients were in the lower exposure group.
Time frame: Baseline to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particles.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Small LDL Particles.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Intermediate LDL Particles.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Large LDL Particles.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12:Total Very Low-Density Lipoprotein (VLDL) and Chylomicron Particles
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL and Chylomicron Particles.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total HDL Particles
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Total HDL Particles.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: LDL Particle Size
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particle size.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: VLDL Particle Size
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL Particle Size.
Time frame: Baseline up to Week 12
Mean Change in Lipid Particle Concentration From Baseline To Week 12: HDL Particle Size
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for HDL Particle Size.
Time frame: Baseline up to Week 12
| Milestone | MGL-3196 | Placebo |
|---|---|---|
| Started | 78 | 38 |
| Received at least 1 dose of study drug | 78 | 38 |
| Completed | 72 | 36 |
| Not completed | 6 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Adverse event | 4 | 2 |
LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change in LDL-C From Baseline To Week 12 | -10.6 ± 2.59 | 8.2 ± 3.71 |
T4 was assessed at each study visit.
| ng/dL | MGL-3196 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 12 of Free Thyroxine (T4) | -0.268 ± 0.0130 | 0.009 ± 0.0185 |
Free T3 was assessed at each study visit.
| ng/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 12 of Free Triiodothyronine (T3) | -0.04 ± 0.038 | 0.10 ± 0.054 |
TSH was assessed at each study visit.
| mIU/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 12 of Thyrotropin (TSH) | -0.027 ± 0.0690 | 0.114 ± 0.0987 |
TBG was assessed at all study visits except the Screening Visit.
| mg/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 12 of Thyroxine Binding Globulin (TBG) | -2.31 ± 0.256 | -0.44 ± 0.367 |
Reverse T3 was assessed at each study visit.
| ng/dL | MGL-3196 | Placebo |
|---|---|---|
| Mean Change From Baseline to Week 12 of Reverse Triiodothyronine (T3) | -4.36 ± 0.392 | -0.58 ± 0.554 |
Non-HDL-C were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Week 12 | -12.0 ± 2.41 | 7.5 ± 3.46 |
Triglycerides were determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change In Triglycerides From Baseline To Week 12 | -18.3 ± 3.24 | 7.2 ± 4.64 |
Lp(a) was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change In Lipoprotein(a) (Lp[a]) From Baseline To Week 12 | -21.8 ± 2.87 | 4.4 ± 4.11 |
Apolipoprotein CIII was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change in Apolipoprotein CIII From Baseline to Week 12 | -19.3 ± 2.9 | 3.4 ± 4.1 |
ApoB was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change In Apolipoprotein B (ApoB) From Baseline To Week 12 | -14.2 ± 1.66 | 3.8 ± 2.37 |
The ApoB/ApoA1 ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change in Apolipoprotein B/Apolipoprotein A1 (ApoB/ApoA1) Ratio From Baseline to Week 12 | -5.0 ± 1.8 | 4.2 ± 2.5 |
The Cholesterol/HDL-C Ratio was determined by ultracentrifugation. LS mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Mean Percent Change In Cholesterol/HDL-C Ratio From Baseline to Week 12 | -3.5 ± 2.3 | 6.3 ± 3.3 |
LDL-C was determined by ultracentrifugation or direct measure . Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| mg/dL | MGL-3196 | Placebo |
|---|---|---|
| Absolute Change in LDL-C From Baseline to Week 12 | -17.0 ± 3.31 | 9.9 ± 4.74 |
LDL-C was determined by ultracentrifugation or direct measure. Least-squares (LS) mean was provided for the comparison of MGL-3196 versus placebo and it used a linear model with percent change from baseline as the dependent variable and treatment as a factor.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Week 2 | -16.6 (-22.6 to -10.6) | 1.6 (-3.2 to 6.5) |
| Week 4 | -9.8 (-16.3 to -3.4) | 0.1 (-5.2 to 5.4) |
The effect on percent change in LDL-C from baseline to Week 12 was determined by patient exposure category (higher/lower). Patients taking MGL-3196 were categorized into lower and higher exposure groups. Patients in the higher exposure group must either have had estimated Week 2 AUC ≥5,000 mg∙h/L, or if Week 2 AUC \<5,000 mg∙h/L but Week 4 pre-dose concentration \>1.5 ng/mL (if on 60 mg MGL-3196). All other patients were in the lower exposure group.
| percent change | MGL-3196 Lower Exposure | MGL-3196 Higher Exposure | Placebo |
|---|---|---|---|
| Percent Change in LDL-C From Baseline to Week 12 by Systemic Exposure Category | -8.1 ± 3.71 | -13.0 ± 3.62 | 8.2 ± 3.71 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particles.
| nmol/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total LDL Particles | 1223 ± 334 | 1428 ± 475 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Small LDL Particles.
| nmol/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: Small LDL Particles | 655 ± 214 | 760 ± 265 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Intermediate LDL Particles.
| nmol/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: Intermediate LDL Particles | 157 ± 96 | 168 ± 184 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Large LDL Particles.
| nmol/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: Large LDL Particles | 411 ± 247 | 501 ± 302 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL and Chylomicron Particles.
| nmol/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12:Total Very Low-Density Lipoprotein (VLDL) and Chylomicron Particles | 24.8 ± 18.5 | 37.3 ± 24.7 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for Total HDL Particles.
| micromol/L | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: Total HDL Particles | 29.79 ± 4.699 | 30.92 ± 5.940 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for LDL Particle size.
| nm | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: LDL Particle Size | 20.94 ± 0.546 | 20.89 ± 0.549 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for VLDL Particle Size.
| nm | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: VLDL Particle Size | 52.27 ± 7.063 | 51.33 ± 8.801 |
The effect of once-daily oral dosing of MGL-3196 versus placebo for 12 weeks in terms of change from baseline was assessed for HDL Particle Size.
| nm | MGL-3196 | Placebo |
|---|---|---|
| Mean Change in Lipid Particle Concentration From Baseline To Week 12: HDL Particle Size | 9.30 ± 0.589 | 9.19 ± 0.586 |
Collected over Baseline (Day 1) up to Week 12. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MGL-3196 | 0/78 (0%) | 0/78 (0%) | 65/78 (83.3%) |
| Placebo | 0/38 (0%) | 1/38 (2.6%) | 28/38 (73.7%) |
| Event | MGL-3196 | Placebo |
|---|---|---|
| PyrexiaGeneral disorders | 0/78 | 1/38 |
| Event | MGL-3196 | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 16/78 | 2/38 |
| DiarrheaGastrointestinal disorders | 15/78 | 4/38 |
| NasopharyngitisInfections and infestations | 10/78 | 6/38 |
| HeadacheNervous system disorders | 10/78 | 6/38 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/78 | 5/38 |
| DizzinessNervous system disorders | 4/78 | 4/38 |
| Alanine aminotransferase increasedInvestigations | 8/78 | 0/38 |
| Aspartate aminotransferase increasedInvestigations | 8/78 | 0/38 |
| Hepatic enzyme increasedInvestigations | 7/78 | 0/38 |
| FatigueGeneral disorders | 7/78 | 2/38 |
| Age, Categorical(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 56 | 25 | 81 |
| >=65 years | 22 | 13 | 35 |
| Age, Continuous(years) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Mean | 56.4 ± 12.38 | 59.1 ± 11.33 | 57.3 ± 12.06 |
| Sex: Female, Male(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Female | 39 | 16 | 55 |
| Male | 39 | 22 | 61 |
| Ethnicity (NIH/OMB)(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 78 | 38 | 116 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 78 | 37 | 115 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Low-density Lipoprotein Cholesterol (LDL-C) (Direct measure or ultracentrifugation)(mg/dL) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Mean | 131.4 ± 47.24 | 137.0 ± 57.53 | 133.3 ± 50.65 |
| Statin Use(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Atorvastatin | 40 | 16 | 56 |
| Rosuvastatin | 34 | 17 | 51 |
| Pravastatin | 1 | 1 | 2 |
| None | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Jan 2018, 10 months.
Results were first posted in Dec 2025, 7 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resmetirom
Hyperlipoproteinemia Type II →
Madrigal Pharmaceuticals, Inc. →